Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Ovaviu fɔ di tin dɛn we dɛn dɔn lan
GLP-2, we na wan nyu mɛrɛsin, dɔn gɛt bɔku atɛnshɔn pan di fild fɔ mɛtabolism tritmɛnt. na di fכs dual agonist fכ di glukagon lεk pεptida-1 (GLP-1) rεsεpכta εn di glukכs-dipεndεnt insulinotropik polipεptida (GIP) rεsεpכta. tru in yכnik mεkanism fכ akshכn, i de miks di nεchכral ifekt dεm we GLP-1 εn GIP de gi, we de gi nyu opshכn fכ kכntrכl glukכs na di bכdi.
Figure 1 di mεkanism dεm fכ akshכn fכ GLP-2 insay di mכtalman bכdi.
Mekanism fɔ Akshɔn
rεgulεshכn fכ insulin εn glukagon sekreshכn: GLP-2 de inkrεs insulin sekreshכn εn ridyus glukagon rilis insay wan we we dipεnd pan glukכs. we di blכd glukכs lεvεl go כp, GLP-2 de mek di pankrεas beta sεl dεm fכ sekret mכr insulin, we de mek di glukכs tek εn yutilizeshכn aksεlεrat εn di blכd glukכs lεvεl de dכn; i de inhibit glukagon sekreshכn bak, i de ridyus di hεpatik glukכs autput, fכ stebul di blכd glukכs lεvεl mכr. dis dual-pronged rεgεdyushכn apכch de εp fכ mεnten di dinamik bכdi glukכs bεlε, ifektivli lכs כl tu di fasting εn postprandial bכdi glukכs lεvεl.
Fɔ mek pɔsin sati ɛn fɔ lɛf fɔ it bɔku bɔku it: Dis mɛrɛsin kin mek pɔsin sati, ɛn dis kin mek di sikman dɛn nɔ it bɛtɛ tin fɔ it ɛn dat kin mek dɛn nɔ gɛt bɔku bɔku bɔdi. Fɔ lɔs yu wet impɔtant fɔ di wan dɛn we gɛt tayp 2 mɛtabolism, bikɔs bɔku tɛm fɔ fat kin gɛt fɔ du wit insulin rɛsistɛns. bay we i de ridyus di wet, GLP-2 de ɛp fɔ mek di insulin sɛnsitiviti bɛtɛ, we de mek di bɔdi de ansa mɔ to insulin ɛn dat de mek i ebul fɔ kɔntrol di glukɔs we de na di blɔd bɛtɛ. apat frכm dat, we yu lכs wet de εp fכ ridyus di risk fכ kכmplikεshכn lεk kכdivaskyul sik na di mεtabolism pasεnshכn dεm.
dilay di gastric εmpty: GLP-2 de delay di gastric εmpty, i de mek di tεm we di it de insay di bεlε lכng εn i de slo fכ go insay di sכmכl intestin, we de mek di bכdi shuga lεvεl nכ de spik kwik kwik wan. Dis ifekt de ɛp fɔ mek di blɔd shuga chenj chenj, mɔ bay we i de kɔntrol di blɔd shuga pik fayn fayn wan, we de mek fayn kɔndishɔn fɔ stebul blɔd shuga kɔntrol.
fכ impruv mεtabolik mak dεm: Apat frכm di ifekt dεm we i de du pan bכdi shuga εn wet, GLP-2 de sho bak fayn ifekt dεm fכ impruv di lipid lεvεl dεm εn כda mεtabolik mak dεm. Klinik stכdi dεm sho se i de εp fכ lכs di lכw-dεnsiti lipoprotein (LDL) kכlestכl εn triglisεrayd lεvεl, εnhans כvala mεtabolik hεlth εn fכ ridyus di risk fכ kכdivaskyul sik pan dayabεtik pasεnshכn dεm.
Aplay fɔm
Insay di kɔmplit SURPASS ɛn SURMOUNT big-big Faz III klinik stɔdi dɛn, GLP-2 sho se i gɛt bɛtɛ blɔd glukɔs kɔntrol ɛfifikɛshɔn. We yu kɔmpia am wit plasɛbo, GLP-2 rili ridyus di ɛmoglobin A1c (HbA1c) lɛvɛl dɛn we i sho bak fayn fayn wet lɔs ifɛkt dɛn. i efikכs pas di wan we di GLP-1 rεsεptכr agonist dεm we dεn apruv naw. Insay sɔm trayal dɛn, di pasɛnt dɛn we dɛn trit wit GLP-2 bin gɛt big ridyushɔn pan HbA1c lɛvɛl ɛn mɔ pronɔns weit lɔs, we sho klia wan se i efyushɔn ɛn i bɛtɛ pas ɔl pan glycemic kɔntrol ɛn wet mɛnejɛmɛnt.
Tritmɛnt fɔ Tayp 2 Dayabitis: As adjɔnt to it ɛn ɛksɛsayz, GLP-2 de gi wan fayn tritmɛnt opshɔn fɔ pasɛnt dɛn we gɛt Tayp 2 mɛtabolism. Ilɛksɛf dɛn yuz am as wan tritmɛnt ɔ dɛn yuz am wit ɔda mɛrɛsin dɛn we de mek pɔsin nɔ gɛt dayabitis, GLP-2 kin rili ɛp di sikman dɛn blɔd glukɔs kɔntrol.
Dɔn
fכ sכmari, GLP-2 de sho advantej dεm fכ blכd glukכs kכntrכl biכs fכ in yכnik mεkanism fכ akshכn εn כtstandin pεrformεns insay klinik trial dεm. i nכ de כnli fכ lכs di blכd glukכs lεvεl bכt i de ple fayn rol fכ di wet mεnejmεnt εn impruv mεtabolik mak dεm.
Sos dɛn we dɛn pul
[1] Sood A, Kaur P, Syed O, ɛn ɔda pipul dɛn. rivכlyushכn mεtabolism kεri: fכ sho di GLP-2 in pכtεnshal in glycemic kכntrכl εn biyכn[J]. Ekspɛkt Rivyu fɔ Klinik Famakɔlɔji, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.
[2] Wong E, Kɔp R, Dima L, ɛn ɔda pipul dɛn. GLP-2: Wan Dual Glucose-dipεndεnt Insulinotropic Polypeptide εn Glucagon-Lεk Pεptid-1 Agonist fכ di Mεnejmεnt fכ Tayp 2 Dayabitis Mεlitus[J]. Amɛrikan Jɔnal fɔ Tɛrapi, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, ɛn ɔda pipul dɛn. Wan Ovaviu pan GLP-2, Dual-Targeted Tritmɛnt fɔ Dayabitis ɛn Ɔbisiti[J]. Int ɛ rnash ɔ nal J ɔ rnal ɔ f Inovativ Risach & Grɔwth, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda V. P., Ajabiya J., Tɛli D, ɛn ɔda pipul dɛn. GLP-2, wan Nyu Era fɔ Dual-Targeted Tritmɛnt fɔ Dayabitis ɛn Ɔbisiti: Wan Mini-Rivyu[J]. Molekyul, 2022,27(13).DOI:10.3390/molikul27134315.
[5] Fɔrzano I, Varzideh F, Avvisato R, ɛn ɔda pipul dɛn. GLP-2: Wan Sistamat Ɔpdet[J]. Int ɛ rnash ɔ nal J ɔ rnal ɔ f Mɔlikul Sayns, 2022,23(23).DOI:10.3390/ijms232314631.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
